Study of TS-1 or TS-1 + PSK for Gastric Cancer Patients

Gastric Cancer Clinical Trial

— TMOG-GC01  

Official title:

Phase III Randomized Controlled Study of Postoperative Adjuvant Therapy Using TS-1 or TS-1+PSK for Stage II or III Gastric Cancer Patients

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00687843
• Other study ID #: TMOG-GC01
• Status: Active, not recruiting
• Phase: Phase 3
• First received: May 28, 2008
• Last updated: March 20, 2012
• Start date: June 2008
• Est. completion date: March 2016

Study information

• Verified date: March 2012
• Source: Tokyo Metropolitan Oncology Group
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Ministry of Health, Labor and Welfare
• Study type: Interventional

Clinical Trial Summary

Since it is not uncertain about efficacy of combination therapy with PSK and TS-1 in gastric cancer, in this study, we compare efficacy and safety of postoperative adjuvant therapy using TS-1 or TS-1+PSK in the stage II or III gastric cancer patients.

Description:

TS-1 is an oral anticancer drug approved in Japan consisting of tegafur (a pro-drug of fluorouracil, 5-FU), gimeracil and oteracil potassium. The response rate of TS-1 in the untreated advanced gastric cancer patients was 44.6% in the late phase II study. In 2007, efficacy of the adjuvant therapy using TS-1 in the resected gastric cancer patients was demonstrated by ACTS-GC study group conducted in Japan. PSK is an oral anticancer drug approved in Japan consisting of protein-bound polysaccharide extracted from mycelium of Trametes (Coriolus) versicolor, a kind of mushroom. Even though survival benefit by PSK in combination with adjuvant chemotherapy using 5-FU or tegafur in the postoperative gastric cancer patients was already demonstrated, it is not uncertain about efficacy of combination therapy with PSK and TS-1 in gastric cancer. In this study, we compare efficacy and safety of postoperative adjuvant therapy using TS-1 or TS-1+PSK in the stage II or III gastric cancer patients.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 480
• Est. completion date: March 2016
• Est. primary completion date: March 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patient who is pathologically confirmed as gastric cancer

• Patient who has received surgery with D2 or more lymph node dissection and whose final curability of surgical resection is grade A or B

• Patient whose final stage is II (except for T1), IIIA, or IIIB

• Patient without liver, peritoneal and distant metastasis, and who is negative in peritoneal cytological diagnosis

• Patient whose age at the registration is ranging between 20 and 80 years old

• Patient who has not received any preoperative therapy including radiotherapy, chemotherapy and immunotherapy

• Patient who has received surgery for gastric cancer within six weeks before the registration, and is judged to be capable of oral administration

• Patient who has no serious concurrent complications, and satisfies the following criteria

• White blood cell count: > LLN or > 4,000 /mm3

• Platelet count: > 100,000 /mm3

• Serum total bilirubin: < 1.5 mg/dL

• Serum AST (GOT), ALT (GPT): < 2.5 * ULN

• Serum creatinine: < ULN

• Patient who has received an explanation of this study by assent documents, and has given written informed consent to participate in this study

Exclusion Criteria:

• Patient with metachronous or synchronous multicancer

• Patient who contraindicates to TS-1

• Patient who requires continuous use of flucytosine, phenytoin or warfarin potassium

• Patient who has experienced serious drug allergy over grade 3 in the past

• Patient with serious complications including paralysis of intestine, ileus, interstitial pneumonitis, fibroid lung, uncontrollable diabetes mellitus, heart insufficiency, renal insufficiency or hepatic insufficiency

• Patient with diarrhea (watery stool)

• Patient who is pregnant or in lactation, or wish to become pregnant during this study

• Male patient who intends to make someone pregnant during this study

• Patient with HIV positive

• Patient who is judged to be inappropriate as subject to this study by the principal investigator or the doctors in charge

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Gastric Cancer
• Stomach Neoplasms

Intervention

Drug:
• Tegafur-gimeracil-oteracil potassium (TS-1)
80 mg/m2, PO from day 1 to day 28 of each 42 day cycle. Number of Cycles: 8
• Krestin (PSK)
3 g, PO from day 1 to day 336

Locations

Country	Name	City	State
Japan	Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital	Tokyo

Sponsors (1)

Lead Sponsor	Collaborator
Tokyo Metropolitan Oncology Group

Country where clinical trial is conducted

Japan, 

References & Publications (2)

Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet. 1994 May 7;343(8906):1122-6. — View Citation

Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007 Nov 1;357(18):1810-20. Erratum in: N Engl J Med. 2008 May 1;358(18):1977. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Relapse-free survival		Five years after surgery	No
Secondary	Overall survival, quality of life, drug compliance, adverse events, serial changes of tumor markers		Five years after surgery	Yes